Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (91-100 of 377) with videos related to

Pageof 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucoseJörg Schwarz-Dose, Michael Untch, Reinhold Tiling, et al.
The Lancet Regional Health. Europe|October 13, 2025
Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based studyXingrong Liu, Behnaz Binicy, Balazs Acs, et al.
Breast Care (Basel, Switzerland)|June 29, 2018
ABC4 Consensus: Assessment by a German Group of ExpertsNadia Harbeck, Diana Lüftner, Norbert Marschner, et al.
Acta Oncologica (Stockholm, Sweden)|October 5, 2019
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancerAntroula Papakonstantinou, Elham Hedayati, Mats Hellström, et al.
Geburtshilfe Und Frauenheilkunde|June 9, 2018
4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German ExpertsMichael Untch, Rachel Würstlein, Norbert Marschner, et al.
The Lancet Regional Health. Europe|December 20, 2024
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trialAlexios Matikas, Andri Papakonstantinou, Sibylle Loibl, et al.
Breast Cancer Research and Treatment|February 5, 2010
Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancerGottfried E Konecny, Giovanni Pauletti, Michael Untch, et al.
Cancer Treatment Reviews|June 17, 2021
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledgeChristian Jackisch, Patricia Cortazar, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) studyMatti Aapro, Robert C Leonard, Agustí Barnadas, et al.
Cancer Research|January 21, 2006
The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancerStefan Wilkening, Justo Lorenzo Bermejo, Barbara Burwinkel, et al.
Pageof 38

Showing results (91-100 of 377) with videos related to

Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucoseJörg Schwarz-Dose, Michael Untch, Reinhold Tiling, et al.
The Lancet Regional Health. Europe|October 13, 2025
Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based studyXingrong Liu, Behnaz Binicy, Balazs Acs, et al.
Breast Care (Basel, Switzerland)|June 29, 2018
ABC4 Consensus: Assessment by a German Group of ExpertsNadia Harbeck, Diana Lüftner, Norbert Marschner, et al.
Acta Oncologica (Stockholm, Sweden)|October 5, 2019
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancerAntroula Papakonstantinou, Elham Hedayati, Mats Hellström, et al.
Geburtshilfe Und Frauenheilkunde|June 9, 2018
4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German ExpertsMichael Untch, Rachel Würstlein, Norbert Marschner, et al.
The Lancet Regional Health. Europe|December 20, 2024
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trialAlexios Matikas, Andri Papakonstantinou, Sibylle Loibl, et al.
Breast Cancer Research and Treatment|February 5, 2010
Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancerGottfried E Konecny, Giovanni Pauletti, Michael Untch, et al.
Cancer Treatment Reviews|June 17, 2021
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledgeChristian Jackisch, Patricia Cortazar, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) studyMatti Aapro, Robert C Leonard, Agustí Barnadas, et al.
Cancer Research|January 21, 2006
The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancerStefan Wilkening, Justo Lorenzo Bermejo, Barbara Burwinkel, et al.
Pageof 38